Kiromic Biopharma

FDA Review: Alnylam, Cytokinetics, Eli Lilly and More
BioSpace
Sun, 10/9/22 - 06:06 pm
FDA
Alnylam
Cytokinetics
Eli Lilly
Owlet
Boston Cell Standards
Kiromic Biopharma
Entera Bio
Transcenta Holdings
Kira Pharmaceuticals
Kite Pharma
Poxel
Seneca Therapeutics
Four biotechs and a Matthew Roden-led SPAC price IPOs, raising a combined $528M
Endpoints
Fri, 10/16/20 - 12:16 pm
IPOs
biotech
SPAC
Matthew Roden
Praxis Precision Medicines
Tarsus Pharmaceuticals
Aligos Therapeutics
Kiromic Biopharma
Tumeric Acquisition
The biotech IPO boom is becoming ‘historic’ as four more throw their hats in
Endpoints
Mon, 06/29/20 - 10:34 am
IPOs
biotech
Berkeley Lights
ALX Oncology
Pandion Therapeutics
Kiromic Biopharma